STATE STREET CORP - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$85,558,924
-6.6%
1,884,973
+15.5%
0.01%0.0%
Q2 2023$91,647,034
+2.0%
1,632,473
-17.8%
0.01%0.0%
Q1 2023$89,833,378
-46.9%
1,986,187
-52.3%
0.01%0.0%
Q4 2022$169,194,730
+65.1%
4,162,232
+165.4%
0.01%
-16.7%
Q3 2022$102,494,000
+7.4%
1,568,384
-0.1%
0.01%0.0%
Q2 2022$95,400,000
+218.3%
1,569,860
+228.8%
0.01%
+500.0%
Q1 2022$29,971,000
+90.5%
477,476
+129.9%
0.00%0.0%
Q4 2021$15,736,000
-13.6%
207,652
+27.7%
0.00%0.0%
Q3 2021$18,205,000
-25.5%
162,642
+7.8%
0.00%0.0%
Q2 2021$24,432,000
+34.3%
150,916
+1.1%
0.00%0.0%
Q1 2021$18,187,000
-12.2%
149,255
+10.3%
0.00%0.0%
Q4 2020$20,725,000
+75.4%
135,361
-4.2%
0.00%0.0%
Q3 2020$11,819,000
+33.1%
141,311
+17.0%
0.00%0.0%
Q2 2020$8,877,000
+193.9%
120,789
+69.6%
0.00%
Q1 2020$3,020,000
+3.2%
71,211
+48.2%
0.00%
Q4 2019$2,927,000
+92.4%
48,052
+29.5%
0.00%
Q3 2019$1,521,000
-11.2%
37,103
+2.1%
0.00%
Q2 2019$1,712,000
+83.9%
36,345
+39.5%
0.00%
Q1 2019$931,000
+23.6%
26,053
-1.1%
0.00%
Q4 2018$753,000
-38.2%
26,353
-4.1%
0.00%
Q3 2018$1,219,000
-14.0%
27,470
+13.8%
0.00%
Q2 2018$1,418,00024,1330.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$27,989,04633.20%
Gilfoyle Management LLC 100$4,84215.90%
NEA Management Company, LLC 1,587,854$89,142,1246.80%
ARK Investment Management 7,338,447$411,980,3942.73%
Nikko Asset Management Americas, Inc. 3,533,357$198,327,3282.09%
Del-Sette Capital Management, LLC 33,661$1,889,7291.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Merlin Capital, Inc 8,802$494,1441.67%
Green Alpha Advisors, LLC 34,373$1,929,7001.27%
View complete list of CRISPR THERAPEUTICS AG shareholders